Shengzhao pharmaceutical recently disclosed the announcement on the guidance, filing and progress of applying for public offering of shares and listing on the Beijing stock exchange. The announcement shows that on December 23, the company and China International Capital Corporation Limited(601995) signed the guidance agreement between Zhejiang shengzhao Pharmaceutical Technology Co., Ltd. and China International Capital Corporation Limited(601995) on public offering of shares to unspecified qualified investors and listing on the Beijing stock exchange, and the guidance organization is China International Capital Corporation Limited(601995) . On December 24, China International Capital Corporation Limited(601995) submitted the guidance filing application materials to Zhejiang securities regulatory bureau.
The announcement shows that according to the 2019 annual report and 2020 annual report disclosed by the company, the total R & D investment of the company in the last two years is 137 million yuan, which is in line with Article 2.1.1 of the listing rules The financial conditions for listing on the Beijing stock exchange specified in Article 3.
(China Securities Journal · China Securities Network)
